Please ensure Javascript is enabled for purposes of website accessibility
Max Macaluso

Max Macaluso

TMFMassimo

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Recent articles

Sanofi and Regeneron's Latest Partnership

Late-stage clinical trials begin for this duo's experimental rheumatoid arthritis drug.


What Does This Failure Mean for Eli Lilly Investors?

Eli Lilly announced that it will stop developing cancer drug candidate enzastaurin. What does this mean for its business?


4 Technologies That Can Help Track Weight Loss

Apps and devices that help patients being treated for obesity track their progress.


This Week in Health Care

For the week ended May 10, 2013.


Why NPS Pharmaceuticals Is Up After Earnings

Orphan drugmaker NPS Pharmaceuticals reveals the progress of its Gattex launch.

3 Key Takeaways From Keryx's Earnings Report

What should investors focus on after this biotech's Q1 report?


Is Orexigen Therapeutics Burning Too Much Cash?

What is this biotech's burn rate?


This Week in Health Care

For the week ended May 3, 2013.


Hot Off the Press: Arena Pharmaceuticals’ First Quarter Results

Initial takeaways from Arena's Q1 report.


Is a Pharmaceutical Company the Same as a Biotech?

Have they become the same, or do they have different approaches to drug discovery?

Teva's 3 Biggest Challenges

Teva is one of the largest pharmaceutical companies in the world, but what roadblocks lie ahead?


1 Simple Way to Be a Better Investor

Trying to weight the pros and cons of a potential investment? SWOT away your worries and try this approach.


2 Upcoming Catalysts for Amarin

Two important events that Amarin investors need to watch.


Why This Obesity Drugmaker's Prescription Data Tells Only Half the Story

Vivus released prescription data for its obesity drug Qsymia last week, but its earnings report is more important.


This Week in Health Care

The Motley Fool's weekly health care show.

Obesity and Weight Management: How Much Weight Loss is Actually Necessary?

Obesity is a serious disease, but 5%-10% of weight loss may be enough to make a dramatic impact on a patient's health.


2 Things Regeneron Investors Need to Watch

Which issues should Regeneron investors focus on today?


How Allergy Season Taught Me an Important Investing Lesson

A look at how big pharma brands and markets its products.


This Week in Health Care

The Motley Fool's weekly health-care show.


Want to Retire Soon? Don't Invest in This Industry!

There are many different strategies investors can use to protect their wealth as they near retirement --- but investing in this industry is a risk that may not be worth taking.